These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 12528318)
41. Worsening myopathy associated with ezetimibe in a patient with McArdle disease. Perez-Calvo J; Civeira-Murillo F; Cabello A QJM; 2005 Jun; 98(6):461-2. PubMed ID: 15897216 [No Abstract] [Full Text] [Related]
42. Statin safety: an appraisal from the adverse event reporting system. Davidson MH; Clark JA; Glass LM; Kanumalla A Am J Cardiol; 2006 Apr; 97(8A):32C-43C. PubMed ID: 16581327 [TBL] [Abstract][Full Text] [Related]
43. Statin safety: lessons from new drug applications for marketed statins. Jacobson TA Am J Cardiol; 2006 Apr; 97(8A):44C-51C. PubMed ID: 16581328 [TBL] [Abstract][Full Text] [Related]
44. The withdrawal of Baycol (cerivastatin). Griffin JP Adverse Drug React Toxicol Rev; 2001 Dec; 20(4):177-80. PubMed ID: 11770168 [No Abstract] [Full Text] [Related]
45. Statin and statin-fibrate use was significantly associated with increased myositis risk in a managed care population. McClure DL; Valuck RJ; Glanz M; Murphy JR; Hokanson JE J Clin Epidemiol; 2007 Aug; 60(8):812-8. PubMed ID: 17606177 [TBL] [Abstract][Full Text] [Related]
46. Review of side-effect profile of combination ezetimibe and statin therapy in randomized clinical trials. Kashani A; Sallam T; Bheemreddy S; Mann DL; Wang Y; Foody JM Am J Cardiol; 2008 Jun; 101(11):1606-13. PubMed ID: 18489938 [TBL] [Abstract][Full Text] [Related]
47. The safety of niacin in the US Food and Drug Administration adverse event reporting database. Alsheikh-Ali AA; Karas RH Am J Cardiol; 2008 Apr; 101(8A):9B-13B. PubMed ID: 18375244 [TBL] [Abstract][Full Text] [Related]
48. The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis. Harper CR; Jacobson TA Curr Opin Lipidol; 2007 Aug; 18(4):401-8. PubMed ID: 17620856 [TBL] [Abstract][Full Text] [Related]
49. Does upsizing statins have a downside? Brown AJ Drug Saf; 2010 May; 33(5):435-6; author reply 436-7. PubMed ID: 20411621 [No Abstract] [Full Text] [Related]
50. Statins and myopathy. Mann S N Z Med J; 2005 Dec; 118(1227):U1798. PubMed ID: 16372038 [No Abstract] [Full Text] [Related]
51. [Withdrawal of cerivastatin revealed a flaw of post-marketing surveillance system in the United States]. Saito M; Hirata-Koizumi M; Miyake S; Hasegawa R Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2005; (123):41-5. PubMed ID: 16541751 [TBL] [Abstract][Full Text] [Related]
52. Statins: putting the benefit/risk into perspective. Shepherd J Int J Clin Pract Suppl; 2003 Oct; (137):27-33. PubMed ID: 14649699 [No Abstract] [Full Text] [Related]
53. Statins and male hypogonadism. Cohen PG J Sex Med; 2011 Jun; 8(6):1826. PubMed ID: 21492398 [No Abstract] [Full Text] [Related]
54. Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks. McKenney JM Am J Cardiol; 2005 Aug; 96(4A):60E-66E. PubMed ID: 16098846 [TBL] [Abstract][Full Text] [Related]
55. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice. Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658 [TBL] [Abstract][Full Text] [Related]
56. [Statins and muscular adverse effects]. Bekken R Tidsskr Nor Laegeforen; 2001 Feb; 121(5):630. PubMed ID: 11301630 [No Abstract] [Full Text] [Related]
57. Fatal and widespread skeletal myopathy confirmed morphologically years after initiation of simvastatin therapy. Boltan DD; Lachar W; Khetan A; Bouffard JP; Roberts WC Am J Cardiol; 2007 Apr; 99(8):1171-6. PubMed ID: 17437752 [TBL] [Abstract][Full Text] [Related]